Prestige Consumer Healthcare (NYSE:PBH) in our automated value investing analysis, with the cash flow history and price comparison below.
Advertisement helps keep Trendshare free for most readers.
Estimate how long you need to hold Prestige Consumer Healthcare to reach your target.
Based on historical returns, we believe that Prestige Consumer Healthcare can grow its free cash at a rate of about 4%. That's positive!
| Advantages | Disadvantages | Neutral |
|---|---|---|
|
|
|
| PBH Price (Prestige Consumer Healthcare stock price per share) |
$49.60 | |
|
|
PBH Fair Price (based on intrinsic value) |
$98.47 |
| PBH Safety Price (based on a variable margin of safety) | $64.01 | |
|
Try your own return
The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value. Value per share: |
||
| PE Ratio versus Sector | 22% lower than other Healthcare stocks | |
| PE Ratio versus Industry | 75% lower than other Drug Manufacturers - General stocks | |
| Cash Yield | 7.61% | |
| Free Cash Flow Jitter | 11% | |
No open-market insider buys or sells are recorded for the last 12 months.
This stock has short interest! This means that people have shorted it.
Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.
As of the latest analysis, there are 4,243,261 shares shorted. With 46,719,801 shares available for purchase and an average trading volume over the past 10 trading days of 719,530, it would take at least 5.9 days for all of the short holders to cover their shorts.
Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth
How to read this: free cash flow in plain terms, free cash flow jitter.
Each year names the SEC filer that reported it, so a change of filer shows up here.
| Fiscal year | SEC filer (CIK) | Free cash flow (USD millions) |
|---|---|---|
| 2010 | 1295947 | 58.8 |
| 2011 | 1295947 | 86 |
| 2012 | 1295947 | 66.8 |
| 2013 | 1295947 | 135 |
| 2014 | 1295947 | 109 |
| 2015 | 1295947 | 152 |
| 2016 | 1295947 | 172 |
| 2017 | 1295947 | 144 |
| 2018 | 1295947 | 205 |
| 2019 | 1295947 | 182 |
| 2020 | 1295947 | 208 |
| 2021 | 1295947 | 223 |
| 2022 | 1295947 | 246 |
| 2023 | 1295947 | 217 |
| 2024 | 1295947 | 236 |
| 2025 | 1295947 | 240 |
| 2026 | 1295947 | 248 |
Download the yearly data as CSV.
How to read this: what free cash flow is, why earnings matter.
Over the 15 fiscal years from 2010 to 2026 with positive net income, operating cash flow totaled $2,625 million against net income of $1,950 million, or 1.35 times. Net income was negative in 2 of the 17 years, and those years are left out of the ratio.
In 2026, operating cash flow was 1.35 times net income, compared with 2.17 times for the earliest three years (2010 to 2012).
In 2026, capital expenditures were $11.2 million, 4.3% of operating cash flow of $258 million, which leaves an estimated $246 million after capex. Across the 17 years with reported capex, it averaged 4.4% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.
Cash conversion in 2026 was 1.35, at least 0.25 under the 2.17 earliest three-year ratio. Gaps like this come from non-cash gains or from cash tied up in receivables, inventory or other working capital.
| Fiscal year | Net income (USD millions) | Operating cash flow (USD millions) | Capital expenditures (USD millions) | Operating cash flow / net income |
|---|---|---|---|---|
| 2010 | 32.1 | 59.4 | 0.7 | 1.85 |
| 2011 | 29.2 | 86.7 | 0.7 | 2.97 |
| 2012 | 37.2 | 67.5 | 0.6 | 1.81 |
| 2013 | 65.5 | 138 | 10.3 | 2.10 |
| 2014 | 72.6 | 112 | 2.8 | 1.54 |
| 2015 | 78.3 | 156 | 6.1 | 2.00 |
| 2016 | 99.9 | 176 | 3.6 | 1.76 |
| 2017 | 69.4 | 149 | 3 | 2.14 |
| 2018 | 340 | 210 | 12.5 | 0.62 |
| 2019 | -35.8 | 189 | 10.5 | n/a |
| 2020 | 142 | 217 | 14.6 | 1.53 |
| 2021 | 165 | 236 | 22.2 | 1.43 |
| 2022 | 205 | 260 | 9.6 | 1.27 |
| 2023 | -82.3 | 230 | 7.8 | n/a |
| 2024 | 209 | 249 | 9.6 | 1.19 |
| 2025 | 215 | 252 | 8.2 | 1.17 |
| 2026 | 190 | 258 | 11.2 | 1.35 |
How to read this: why companies buy back shares, dividend yield explained.
Over the 7 fiscal years from 2019 to 2026 with dividend or share repurchase facts, estimated free cash flow totaled $1,555 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.
In 7 of the 7 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $401 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.
In 2026, cash spent repurchasing shares was $156 million, 62.9% of estimated free cash flow of $248 million.
| Fiscal year | Estimated free cash flow (USD millions) | Dividends paid (USD millions) | Cash spent repurchasing shares (USD millions) | Total returned (USD millions) | Total as a percent of estimated free cash flow |
|---|---|---|---|---|---|
| 2019 | 182 | n/a | 50 | 50 | 27.4% |
| 2020 | 208 | n/a | 56.7 | 56.7 | 27.2% |
| 2021 | 223 | n/a | 11.9 | 11.9 | 5.3% |
| 2023 | 217 | n/a | 50 | 50 | 23.1% |
| 2024 | 236 | n/a | 25 | 25 | 10.6% |
| 2025 | 240 | n/a | 51.5 | 51.5 | 21.5% |
| 2026 | 248 | n/a | 156 | 156 | 62.9% |
Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.
How to read this: earnings and margins.
Revenue was $293 million in 2010 and $1,089 million in 2026, a compound annual growth rate of 8.6% over 16 years.
Revenue fell 4.3% from 2025 to 2026.
Our estimated free cash flow was $248 million in 2026, 22.8% of revenue. In 2010 the estimated margin was 20.1%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.
| Fiscal year | Revenue (USD millions) | Estimated free cash flow (USD millions) | Estimated free cash flow / revenue |
|---|---|---|---|
| 2010 | 293 | 58.8 | 20.1% |
| 2011 | 337 | 86 | 25.6% |
| 2012 | 441 | 66.8 | 15.1% |
| 2013 | 617 | 135 | 21.8% |
| 2014 | 596 | 109 | 18.2% |
| 2015 | 713 | 152 | 21.3% |
| 2016 | 806 | 172 | 21.3% |
| 2017 | 882 | 144 | 16.3% |
| 2018 | 1,041 | 205 | 19.6% |
| 2019 | 976 | 182 | 18.7% |
| 2020 | 963 | 208 | 21.6% |
| 2021 | 943 | 223 | 23.6% |
| 2022 | 1,087 | 246 | 22.6% |
| 2023 | 1,128 | 217 | 19.2% |
| 2024 | 1,125 | 236 | 21.0% |
| 2025 | 1,138 | 240 | 21.1% |
| 2026 | 1,089 | 248 | 22.8% |
How to read this: how debt and assets are compared, the current ratio.
In 2026, cash and equivalents were $63.9 million against total liabilities of $1,607 million, or 4.0% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.
Total liabilities were 46.0% of total assets in 2026, compared with 65.8% in 2011, a decrease of 19.8 percentage points.
Stockholders equity was $1,888 million in 2026, compared with $362 million in 2011, a rise of 421.7%.
Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 7.5% in 2026. Invested capital here is total assets less cash and current liabilities.
| Fiscal year | Total assets (USD millions) | Cash and equivalents (USD millions) | Total liabilities (USD millions) | Stockholders equity (USD millions) |
|---|---|---|---|---|
| 2011 | 1,057 | 13.3 | 695 | 362 |
| 2012 | 1,758 | 19 | 1,356 | 403 |
| 2013 | 1,740 | 15.7 | 1,262 | 478 |
| 2014 | 1,796 | 28.3 | 1,232 | 563 |
| 2015 | 2,642 | 21.3 | 2,014 | 628 |
| 2016 | 2,949 | 27.2 | 2,204 | 744 |
| 2017 | 3,911 | 41.9 | 3,089 | 823 |
| 2018 | 3,761 | 32.5 | 2,582 | 1,179 |
| 2019 | 3,441 | 27.5 | 2,345 | 1,096 |
| 2020 | 3,514 | 94.8 | 2,343 | 1,171 |
| 2021 | 3,429 | 32.3 | 2,071 | 1,358 |
| 2022 | 3,671 | 27.2 | 2,093 | 1,578 |
| 2023 | 3,354 | 58.5 | 1,907 | 1,447 |
| 2024 | 3,318 | 46.5 | 1,663 | 1,655 |
| 2025 | 3,402 | 97.9 | 1,567 | 1,835 |
| 2026 | 3,494 | 63.9 | 1,607 | 1,888 |
How to read this: discounted cash flow, intrinsic value.
At today's price of $49.60, our model's value equals that price if free cash flow grows an average of -22.6 percent a year over the 10 projection years. Our model assumes 4.1 percent a year for this stock, so the price implies growth of -22.6 percent, which is below the 4.1 percent our model assumes. This is the growth the price implies under our model, not a forecast of growth or a price target.
A negative rate means the price matches our model's value only if free cash flow shrinks by that average each year over the 10 years.
The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.
The model starts from the company's average free cash flow of $183 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.
The baseline is the company's average free cash flow, and cyclical companies can mislead it.
| Case | Price per share | Average annual free cash flow growth |
|---|---|---|
| 20 percent below the current price | $39.68 | below range |
| Current price | $49.60 | -22.6% |
| 20 percent above the current price | $59.52 | -11.3% |
| Our model (stored fair price) | $98.47 | 4.1% |
Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.
Every one of the 17 fiscal years we have for Prestige Consumer Healthcare under its current filer shows positive free cash flow.
Free cash flow from the first three years of data averaged $70.5 million, and from the last three $242 million: a sharp rise.
Year-to-year variability in free cash flow is unusually steady, measured at 11%.
With the price at $49.60, Prestige Consumer Healthcare is below both our safe value ($64.01) and our fair value ($98.47).
Dividends are not in our data for Prestige Consumer Healthcare.
Our value investing guide explains how to test these numbers against the filings themselves.
How to read this: the price to earnings ratio.
Its trailing P/E ratio is 22% below the average for stocks in the Healthcare sector.
Its trailing P/E ratio is 75% below the average for stocks in the Drug Manufacturers - General industry.
A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.
These are companies in the Drug Manufacturers - General industry, the ones closest in market capitalization to Prestige Consumer Healthcare, limited to companies whose pages we publish. The figures come from our latest data for each company.
| Company | Market cap (USD millions) | P/E | Dividend yield | Cash yield | Price versus our estimate |
|---|---|---|---|---|---|
| Prestige Consumer Healthcare (PBH) | 2,351 | 15.3 | - | 7.6% | 50% below |
| Perrigo Company plc (PRGO) | 2,226 | - | 6.8% | 68.6% | 91% below |
| ANI Pharmaceuticals (ANIP) | 1,571 | 14.0 | - | - | 190% above |
| Phibro Animal Health Corporation (PAHC) | 1,384 | 13.6 | 1.3% | - | 87% above |
| Innoviva (INVA) | 1,309 | 7.8 | - | - | 12% above |
| Amphastar Pharmaceuticals (AMPH) | 1,199 | 12.9 | - | 0.8% | 97% above |
| Collegium Pharmaceutical (COLL) | 783 | 23.1 | - | - | 160% above |
Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.
Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.
Every fiscal year on this page is reported by one SEC filer, CIK 1295947.
Each figure on this page comes from that filer.
How to read this: understanding investment risk.
Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.
Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.
The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.
This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.
Read the filings yourself: PBH annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.
Advertisement supports free stock analysis content.
Does Prestige Consumer Healthcare have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
This example shows how we apply the Trendshare checklist to PBH: earnings power, cash generation, valuation, and margin of safety.
We check: business quality, free cash flow, P/E, and margin of safety.
Most Popular Articles
What is Dollar Cost Averaging?
Benjamin Graham, Value Investor
How Do Tariffs Affect the Stock Market?
Precious Metals for Value Investors